What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It represents the next generation of incretin-based therapies because it targets two hormonal pathways simultaneously.
While semaglutide activates only GLP-1 receptors, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism produces more pronounced effects on appetite, insulin sensitivity, and fat metabolism — resulting in the highest average weight loss of any FDA-approved medication to date.
In the SURMOUNT-1 trial, participants on tirzepatide 15mg lost an average of 22.5% of body weight over 72 weeks — more than any previously tested anti-obesity medication.
How Tirzepatide Works: The Dual-Agonist Advantage
Tirzepatide's dual mechanism creates a synergistic effect that neither pathway can achieve alone:
- GLP-1 Pathway: Suppresses appetite via hypothalamic signaling, slows gastric emptying, and stimulates glucose-dependent insulin secretion — identical to semaglutide's primary mechanism.
- GIP Pathway: Enhances insulin sensitivity in adipose tissue, promotes more efficient fat oxidation, and may improve leptin sensitivity — the hormone that tells your brain how much fat you're storing. This additional pathway is believed to drive the superior weight loss results.
- Combined Effect: The dual action produces greater caloric reduction, improved glucose homeostasis, and enhanced lipid metabolism compared to GLP-1-only agents. Patients consistently report even more significant reduction in food noise and cravings.
The Most Powerful GLP-1 Class Available
Compounded Tirzepatide starting at $99 first month promo. Affirm financing from $25/mo. Dual-action GIP/GLP-1. Licensed clinicians. 24-hour approval.
Claim $99 First MonthTirzepatide Dosing & Titration Schedule
| Weeks | Dose | Purpose |
|---|---|---|
| 1–4 | 2.5 mg | Initial tolerance phase |
| 5–8 | 5.0 mg | First therapeutic dose |
| 9–12 | 7.5 mg | Intermediate escalation |
| 13–16 | 10.0 mg | Enhanced therapeutic dose |
| 17–20 | 12.5 mg | Advanced dose (if needed) |
| 21+ | 15.0 mg | Maximum dose |
Clinical Trial Results
- SURMOUNT-1: 2,539 adults without diabetes. At the 15mg dose, average weight loss was 22.5% of body weight over 72 weeks. 63% of participants lost ≥20% of body weight.
- SURMOUNT-2: In adults with Type 2 Diabetes, tirzepatide produced 12.8–14.7% weight loss vs. 3.2% with placebo, with HbA1c reductions of 2.1–2.4 percentage points.
- SURMOUNT-3: After an initial lifestyle-only weight loss phase, adding tirzepatide produced an additional 18.4% weight loss vs. 2.5% weight regain with placebo — demonstrating its power even after behavioral interventions.
- SURMOUNT-4: Patients who switched from tirzepatide to placebo regained 14% body weight over 52 weeks, while those who continued lost an additional 5.5% — supporting the value of sustained treatment.
Side Effects & Safety
Similar to semaglutide, the most common side effects are gastrointestinal and typically improve during titration:
- Nausea (most common during dose escalation)
- Diarrhea or constipation
- Decreased appetite (a therapeutic effect)
- Injection site reactions
Contraindications include personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome. Your Telehealth FX clinician conducts a thorough screening before prescribing.
Who Should Consider Tirzepatide?
- Adults seeking the maximum weight loss potential from GLP-1 therapy
- Patients who have plateaued on semaglutide and want to escalate treatment
- Individuals with significant insulin resistance or Type 2 Diabetes
- Those willing to invest in the most effective obesity medication available
Real Patient Reviews & Clinical Outcomes
"Switched from Semaglutide to Tirzepatide and the results accelerated dramatically. Down 41 lbs in 4 months with virtually no appetite. Life-changing."
"The dual-action mechanism really works. My blood sugar is better than it's been in years and I've lost 35 lbs. The telehealth process made everything easy."
Start Your Tirzepatide Program
From $99 first month promo. Regular renewal from $214/mo. Affirm financing available from $25/mo. 24-hour approval. Free cold shipping.
Claim $99 First MonthDisclaimer: Compounded medications are prepared by state-licensed 503A and 503B compounding pharmacies pursuant to a patient-specific prescription. Compounded medications are not reviewed or approved by the FDA for safety, efficacy, or quality. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Telehealth FX is an independent telehealth platform and is not affiliated with or endorsed by Eli Lilly and Company.